Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …

Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …

Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …

Purpose Although sorafenib enhances overall survival, sorafenib resistance has been
reported to be a significant limiting factor for improved prognosis in patients with …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

Purpose Sorafenib, a multikinase inhibitor, is the standard therapy for patients with
advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the …

Background To provide support for combined usage of phosphoinositide 3-kinase (PI3K)
inhibitors or mitogen-activated protein kinase pathway inhibitors together with sorafenib in …

Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …

Sorafenib is the first FDA-approved therapeutic drug for molecular target medication on
advanced-stage hepatocellular carcinoma. It is reported that sorafenib could improve the …